Oral retinoids-efficacy and toxicity in psoriasis

British Journal of Dermatology, Supplement

Volumn 135, Issue 49, 1996, Pages 6-17

  Gollnick, H P M ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DITHRANOL; ETRETIN; ETRETINATE; GLUCOCORTICOID; LIVER ENZYME; METHOTREXATE; PSORALEN DERIVATIVE; RETINOID;

ALOPECIA; CHEILITIS; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PSORIASIS; ULTRAVIOLET RADIATION;

ADMINISTRATION, ORAL; FEMALE; HUMANS; PSORIASIS; RETINOIDS; TERATOGENS;

EID: 0029835838     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb15661.x     Document Type: Article

References (80)

1. Christophers E, Krueger GG. Psoriasis. In: Dermatology in General Medicine (Fitzpalrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, eds) New York: McGraw-Hill Book Company, 1987: 461-91.
2. Greaves MW, Weinstein GD. Treatment of psoriasis. New Engl J Med 1995: 332: 581-8.
3. Phillips WG. Breathnach SM. Psoriasis. Immune indicators and treatment. Clin Iimmmother 1994: 1: 157-67.
4. Liem WH, McCullough JL. Weinstein GD. Is topical therapy elTeclive for psoriasis: results of survey of US dermatologists. J Invest Dennatol 1992; 98: 602 (Abstract).
5. Drake LA, Ceilley RI, Cornelison RL et al. Guidelines of care for psoriasis. J Am Acad Dennatol 1993; 28: 632-7.
6. Roenigk Jr HH. Retinoids and other treatments in psoriasis: risk/ benefit ratio. In: Retinoids: 10 Years On (Saurat J-H, ed). Basel: Karger, 1991; 332-40.
7. Altmeyer PJ, Matthes U. Pawlak F et al. Antipsoriatic effect of fumaric acid derivatives: results of a multicenter double-blind study in 100 patients. J Am Acad Dennatol 1994; 30: 977-81.
8. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dennatol 1993; 28: 454-9.
9. Löwe NJ. Systemic retinoid therapy. In: Therapy of Moderate-toSevere Psoriasis (Weinstein GD, Gottlieb AB, eds). Portland: National Psoriasis Foundation. 1993: 94-105.
10. van de Kerkhof PCM, Volden G, Gollnick H. Comparisons and combinations. In: Textbook of Psoriasis (Mier PD, van der Kerkhof PCM, eds). Edinburgh: Churchill Livingstone, 1986: 268-75.
11. Phillips TJ, Dover JS. Recent advances in dermatology. New Engl J Med 1992: 326: 167-78.
12. Bauer R. Orfanos CE. Impaired motility and random migration of vital polymorphonuclears in vitro after therapy with oral aromatic retinoid in psoriasis. lut }Dennatol 1984: 1: 72-7.
13. Weinstein GD, Krueger GG. An overview of psoriasis. In: Therapy of Moderate-to-Severe Psoriasis (Weinstein GD, Gottlieb AB, eds). Portland: National Psoriasis Foundation, 1993: 1-22.
14. Stadier R, Müller M. Detmar M, Orfanos CE. Retinoids and keratinocyte differentiation in vitro. Dermatologica 1987: 175 (Suppl. I): 45-55.
15. Raynaud F. Gerbaud P. Evain-Brion D. Beneficial effect of a combination of retinoids and long-acting theophylline in the treatment of psoriasis vulgaris. Er J Dennatol 1994: 31: 740-2.
16. Stüttgen G. Zur Lokalbehandlung von Keratosen mit Vitamin Asäure. Dermatologica 1962; 124: 65-80.
17. Baer R. Untersuchungen über die Wirkung der Vitamin-A-säure. Dermatoloaica 1962: 124: 192-5.
18. Frost P, Weinstein GD. Topical administration of vitamin A acid for Ichthyosiform dermatoses and psoriasis. J Am Med Assoc 1969; 207: 1863-8.
19. Fredriksson T. Antipsoriatic activity of retinoic acid (vitamin A acid). Dermatologica 1971; 142: 133-6.
20. Schumacher A. Stuttgen G. Vitamin A-säure bei Hyperkeratosen, epithelialen tumoren und akne. Orale und lokale Anwendung. Dtsch Med Wochensclir 1971; 96: 1547-51.
21. Günther S. The therapeutic value of retinoic acid in chronic, acute, guttäte, and erythrodermic psoriasis: clinical observations on twenty-five patients. Br J Dermatol 1973; 89: 515-17.
22. Runne U, Orfanos CE, Gartmann H. Perorale Applikation zweier Derivate der Vitamim A-säure zur internen Psoriasis-thérapie (13cis-beta-vitamin A-säure und vitamin A-säure-athylamid). Arch Dermatol Res 1973; 247: 171-80.
23. Bischoff R, De Jong EMGJ, Rulo HFC et al. Topical application of 13-ds-retinoic acid in the treatment of chronic plaque psoriasis. Clin Exp Dermatol 1992; 17: 9-12.
24. Wozel A, Chang A, Zultak M et al. The effect of topical retinoids on the leukotriene-B-i-induced migration of polymorphonuclear leukocytes into human skin. Arch Dermatol Res 1991; 283: 158-61.
25. Gollnick H. New indications and new retinoids. Dermatologica 1987; 175 (Suppl. I): 182-95.
26. Gollnick H. Orfanos CE. Clinical efficacy of etretinate and acitretin: European experiences. In: Psoriasis (Roenigk HH Jr, Maibach HI, eds) 2nd ed. New York: Dekker. 1991: 725-48.
27. Menter A. Barker JNWN. Psoriasis in practice. Lancet 1991; 338: 231-4.
28. Ott F, BoIIag VV. Traitement oral des formes graves de psoriasis par un analogue de la vitamine A acide. Annal Dermatol 1976: 103: 619-20.
29. Fredriksson T. Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978: 157: 238-44.
30. Ellis CM. Voorhees JJ. Etretinate therapy. J Am Acad Dermatol 1987; 16:267-91.
31. Shahidullah M, Tham S-N, Goh C-L. Etretinate therapy for psoriasis and other keratinising disorders: a 10-year retrospective study in Singapore. Int J Dermatol 1993; 32: 686-9.
32. Halioua B, Saurat J-H. Risk:benefit ratio in the treatment of psoriasis with systemic retinoids. Br J Dermatol 1990; 122 (Suppl. 36): 135-50.
33. Ellis CM. Hermann RC, Gorsulowsky DC et al. Etretinate therapy reduces inpatient treatment of psoriasis. J Am Acad Dermatol 1987; 17: 787-91.
34. Schröder K, Zaun H, Holzmann H et al. Pustulosis palmoplantaris. Clinical and histological changes during etretin (acitretin) therapy. Ada Denn Venereal (Stockh) 1989; 146: 111-16.
35. Lauharanta J, Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br I Dermatol 1989; 121: 107-12.
36. Honigsmann H, Calzavara-Pinton PG, Ortel B. Phototherapy and photochemotherapy. In: Psoriasis (Dubertret L, ed) Brescia: JSED, 1994: 135-50.
37. Fritsch PO, Honigsmann H, Jaschke E, WolffK. Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative. J /vest Dermatol 1978: 70: 178-82.
38. Parker, S, Cobum P, Lawrence C et al. A randomized double-blind comparison of PU VA-etreünate and PUVA-pIacebo in the treatment of chronic plaque psoriasis. Br] Dennatol 1984: 110: 215-20.
39. Saurat J-H. Geiger J-M, Amblard P et al. Randomized double-blind multicenter sludy comparing acitretin-PUVA, etretinale-PUVA and placebo PUVA in the treatment of psoriasis. Dennatologica 1988: 177:218-24.
40. Ruzicka T, Sommerburg C. Braun-Falco 0 et ni Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dennatol 1990: 126: 482-6.
41. lest J, Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br] Dennatol 1989: 120: 665-70.
42. Grupper CH, Beretti B. Retinoid combinations. In: Psoriasis (Roenigk HH Jr. Maibach HI, eds). 2nd edn. New York: Marcel Dekker, 1991: 775-82.
43. Orfanos CE, Goerz A. Orale Psoriasis-thérapie mit einem neuen aromatischen Retinoid (Ro 10-9359). Eine multizentrische kontrollierte Studie an 291 Patienten in der Bundesrepublik. Dtscli Med Wochenschr 1978: 103: 195-9.
44. Van der Rhee HJ, Tijssen JGP, Herrmann WA ft al Combined treatment of psoriasis with a new aromatic retinoid (Tigason) in low dosage orally and triamcinolone acetonide cream topically: A double-bKnd trial. Br J Dennatol 1980; 102: 203-12.
45. van der Veen EE et al. Methotrexate and etretinate as concurrent therapies in severe psoriasis. Arch Dcrniatol 1982; 118: 660-2.
46. Tuyp E. MacKie RM. Combination therapy for psoriasis with methotrexate and etretinate. J Am Acnd Dennatol 1986; 14: 70-3.
47. Rosenbaum MM. Roenigk HH. Treatment of generalized pustular psoriasis with etretinate (Ro 10-9359) and methotrexate. J Am Acad Dennatol 1984; 10: 357-61.
48. Larsen FG. Nielsen-Kudsk F, Jakobsen P et al. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Phannacol 1990: 30: 802-7.
49. Kragballe K, Gjertsen BT, De Hoope D et al. Double-blind, right-left comparison of calcipotriol and betamethasone valereate in the treatment of psoriasis. Lancet 1991; 337: 193-6.
50. Smith EL. U'alworth NC. Holick MF. Effects of 1.25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of culture human epidermal keratinocytes grown in serum-free conditions. J Invest Dennatol 1986; 86: 709-14.
51. Langner A, Stapör V, U'olska H. Combined treatment of chronic plaque psoriasis with etretinate and topical 1,2 5-dihydroxyvitamin D3. J Dennatol Treat 1995; 6: 53 (Abstract).
52. Kingston TP. Matt LH. Löwe NJ. Etretin therapy for severe psoriasis. Arch Dennatol 1987; 123: 55-8.
53. 3 Goldfarb MT, Ellis CN, Gupta AK et al. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dennatol 1988; 18: 655-62.
54. Gollnick H, Bauer R, Brindley C et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dennatol 1988; 19: 458-69.
55. 5 Kragballe K, Jansen CT, Geiger JM et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Acta Derm Venerol (Stockh) 1989; 69: 35-40.
56. Lassus A, Geiger JM, Nyblom M et al. Treatment of severe psoriasis with etretin (Ro 10-1670). Br J Dennatol 1987; 117: 333-41.
57. Gollnick H, Zaun H, Ruzicka T et al. Relapse rate of severe generalised psoriasis after treatment with acitretin or etretinate. Results of the first randomised double-blind multicenter half-year follow-up study. Enr J Dennatol 1993; 3: 442-6.
58. Gollnick H. Acitretin in psoriasis: an update. In: Retinoids: 10 Years On (Saurat J-H, ed). Retinoid Symposium. Geneva. Krager, Basel, 1991:204-13.
59. Orfanos CE, Ehlert R, Gollnick H. The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs 1987: 34:459503.
60. Vahlquist C, Lithell H, Michaé'lsson G et al. Plasma fat elimination, tissue lipoprotein lipase activity and plasma fatty acid composition during sequential treatment with etretinate and isotretinoin. Ada Derm Venereal (Stockh) 1987: 67: 139-44.
61. Kanffman RE, Banner Jr W, Berlin Jr C et al. Retinoid therapy for severe dermatological disorders. Pediatrics 1992; 90 (Part 1): 119-120.
62. Gollnick H, Schwartzkopff W. Pröschle W et al. Retinoids and blood lipids: an update and review. In: Retinoids: Kew Trends in Research and Therapy (Saurat, cd), Basel: Karger, 1985; 445-60.
63. Gupta AK, Goldfarb MX, Ellis CN. Voorhees JJ. Side effect profile of acitretin therapy in psoriasis. J Am Acad Dermatol 1989; 20: 1088-93.
64. Stern RS, Fitzgerald E, Ellis CN el al. The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Academy of Dermatology 1995; 33: 44-52.
65. Nesher G, Zuckner J. Rheumatologic complications of vitamin A and retinoids. Sem Arth Rheum 1995; 24: 291-6.
66. McGuire J, Lawson JP. Skeletal changes associated with chronic isotretinoin and etretinate administration. Dermatologica 1987; 175 (Suppl 1): 169-81.
67. Auffret N, Buisset S. Ocular tolerance of acitretin in 10 patients. In: Retinoids: 10 Years On (Saurat J-H, ed). Basel: Karger, 1991; 327-31.
68. Ward A, Brogden RN, Heel RC et al Etretinate: A review of its pharmacological properties and therapeutic efficacy in psoriasis and other skin disorders. Drugs 1983; 26: 9-43.
69. Mitchell AA. Oral retinoids. What should the prescriber know about their teratogenic hazards among women of child-bearing potential? Drug Safety 1992: 7: 79-85.
70. Teratology Society Position Paper. Recommendations for vitamin A use during pregnancy. Teratology 1987; 35: 269-75.
71. Anon. Retinoids have a major role in dermatology but are limited by teratogenicity. Drugs Ther Perspect 1993: 1: 7-10.
72. Workshop of the Research Unit of the Royal College of Physicians of London. Department of Dermatology, University of Glasgow: British Association of Dermatologists. Guidelines for management of patients with psoriasis. Br Med J 1991; 303: 829-35.
73. Pilkington T, Brogden R. Acitretin. A review of its pharmacology and therapeutic use. Drugs 1992; 43: 597-627
74. Kochhar DM, Nau H, Penner JD et al. Developmental toxicity of retinoids and mode of action. Teratology 1985: 31: 25A-26A.
75. Zimmermann B, Tsambaos D. Evaluation of the sensitive steps of inhibition of chondrogenesis by retinoids in limb mesenchymal cells in vitro. Cell Diff 1985; 17: 95-103.
76. Chou RC, Wyss R, Huselton CA, Wiengand UW. A potentially new metabolic pathway: ethylesterification of acitretin. Xenobiotica 1992:22:993-6.
77. Laugier JP, de Sousa G, Bun H et al. Acitretin biotransformation into etretinate: role of ethanol on in vitro hepatic metabolism. Dermatol 1994; 188: 122-5.
78. Larsen GL, Jacobsen P, Knudsen J et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by alcohol. J Invest Dermatol 1993; 100: 623-7.
79. Anon. F-D-C Report-The Pink Sheet'. Feb 21, 1994; 11.
80. Sturkenboom MCJM. Dejong-van den Berg LTW. van Voorst- ' Vader PC et al. Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment. Br J Clin Pharm 1994: 38: 229-35.